Abstract
BackgroundMajor depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expression levels after antidepressant treatment and investigate differences in protein expression between MDD patients and healthy individuals.MethodsA total of 111 proteins obtained from literature review were subjected to multiple reaction monitoring (MRM)-based protein quantitation. Finally, seven proteins were quantified for plasma specimens of 10 healthy controls and 78 MDD patients (those at baseline and at 6 weeks after antidepressant treatment of either selective serotonin reuptake inhibitors (SSRIs) or mirtazapine).ResultsAmong 78 MDD patients, 35 patients were treated with SSRIs and 43 patients were treated with mirtazapine. Nineteen (54.3%) and 16 (37.2%) patients responded to SSRIs and mirtazapine, respectively. Comparing MDD patients with healthy individuals, alteration of transthyretin was observed in MDD (P = 0.026). A few differences were observed in protein levels related to SSRIs treatment, although they were not statistically significant. Plasma thyroxine-binding globulin (TBG) was different between before and after mirtazapine treatment only in responders (P = 0.007).ConclusionsIn proteomic analysis of plasma specimens from MDD patients, transthyretin and TBG levels were altered in MDD and changed after antidepressant treatment.
Highlights
Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers
The objective of this study was to perform multiple reaction monitoring (MRM)-based proteomic analysis to identify proteins whose expression levels were changed after antidepressant treatment, that might be able to predict treatment response, and assess differences in protein expression between MDD patients and healthy individuals
We identified a difference in plasma transthyretin concentration between MDD patients and healthy individuals, and a change in plasma thyroxine-binding globulin (TBG) concentration related to mirtazapine treatment
Summary
Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expres‐ sion levels after antidepressant treatment and investigate differences in protein expression between MDD patients and healthy individuals. Major depressive disorder (MDD) is a psychiatric disorder with heterogeneous symptoms, including distinct change of mood, sadness, and psychophysiological changes sleep and appetite disturbances [1]. Many previous studies have reported that patients with MDD show various kinds of biological disturbance, including abnormal functioning of neurotransmitters [4], inflammatory changes [5], and dysregulation of the. There are no firm biomarkers for diagnosis of MDD [10], leading to the lack of objective diagnostic tool and misdiagnosis of MDD, especially in primary care setting [10]. At least one-third of patients treated with second-generation antidepressants do not achieve treatment responses [11, 12], there is no relevant biomarker to predict antidepressant treatment response either
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
